For the quarter ended March 2025, Haemonetics (HAE) reported revenue of $330.6 million, down 3.7% over the same period last year. EPS came in at $1.24, compared to $0.90 in the year-ago quarter.
The reported revenue represents a surprise of +1.00% over the Zacks Consensus Estimate of $327.34 million. With the consensus EPS estimate being $1.22, the EPS surprise was +1.64%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Haemonetics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net revenues- Plasma: $126.74 million versus $127.03 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -8.6% change.
- Net revenues- Hospital: $147.86 million versus the three-analyst average estimate of $147.41 million. The reported number represents a year-over-year change of +14.5%.
- Net revenues- Blood Center: $56.01 million compared to the $53.14 million average estimate based on three analysts. The reported number represents a change of -20.3% year over year.
View all Key Company Metrics for Haemonetics here>>>
Shares of Haemonetics have returned +14.8% over the past month versus the Zacks S&P 500 composite's +13.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
